Multiple Choice

A pharmaceutical company holds an exclusive patent for a new life-saving drug, making it the sole provider. The company sets the price for the drug significantly higher than the cost of producing one additional dose. Consequently, some patients who would be willing to pay an amount greater than the production cost are unable to afford the drug. Why is this market outcome considered inefficient?

0

1

Updated 2025-09-20

Contributors are:

Who are from:

Tags

Economics

Economy

Introduction to Microeconomics Course

CORE Econ

Social Science

Empirical Science

Science

Analysis in Bloom's Taxonomy

Cognitive Psychology

Psychology

Related